最近的研究已经确定了MPNST中的多梳阻抑复合物2（PRC2）核心成分

Recent studies have identified repeated mutations in the core components of the polycomb repressor complex 2 (PRC2), embryonic ectoderm development protein (EED), and zeste 12 homolog inhibitor (SUZ12) in MPNST. In most MPNSTs, the identification of EED and SUZ12 mutations in the PRC2 component may suggest the unconventional carcinogenic activity of the complete component EZH2, and provide new opportunities for therapeutic intervention.

Recent studies have identified repeated mutations in the core components of MPNST's polysacculion inhibitor 2 (PRC2), the exomer developmental protein (EED) and the zeste 12 homologous inhibitor (SUZ12). In most MPNST, the identification of the EED and SUZ12 mutations of the PRC2 componentmay imply the non-conventional carcinogenic activity of the complete component EZH2 and provide new opportunities for therapeutic intervention.

Recent studies have identified repeated mutations in the core component of the multi comb inhibitory complex 2 (PRC2), the embryonic ectodermal development protein (EED) and the inhibitor of zeste 12 homologues (Suz12) in MPNST. In most MPNSTs, the identification of EED and Suz12 mutations in PRC2 component may indicate the unconventional carcinogenic activity of the intact component EZH2, and provide a new opportunity for therapeutic intervention.<br>